Sarah Almond
Vice President - Translational Biology NRG Therapeutics
Sarah has nearly 30 years of drug discovery and translational biology experience. She has led biology and pharmacology teams at Astellas, Mission Therapeutics, Charles River Laboratories, Takeda, AstraZeneca, and MSD and advanced multiple small-molecule programs from discovery through to clinical development.
Seminars
Wednesday 2nd December 2026
Translating Multimodal Biomarker Strategies from Preclinical Models to Early Clinical Development in ALS
11:30 am
- Building a multimodal biomarker strategy across early development: integrating blood-based transcriptomics, CSF markers, pharmacodynamic readouts, and disease-relevant endpoints in a Phase I ALS programme
- Leveraging public datasets to de-risk biomarker selection by mining gene expression and proteomic data to identify translatable signatures, aligning preclinical model readouts with human datasets, and validating candidates through access to patient-derived samples
- Designing biomarkers for small, early-phase cohorts through selecting and prioritising analytes, developing bespoke assays, and ensuring translational relevance ahead of patient readouts
NEW DATA
